Fast-track

Finding the right antidepressant.

World first understanding of how antidepressants reach the brain.

With advanced gene testing, we've figured out how readily antidepressants reach the brain.
watch the video doctor briefing

Clinical evidence.

We have the first positive RCT clinical trial. Evidence indicates gene guided treatment can double your odds of recovery.
read the study

Read the replication study showing CNSDose has over 85% accuracy.
read the study

Latest News.

Melbourne startup CNSDose enters one of the world’s largest medical centres to improve the treatment of depression

An Australian medtech startup has entered a four-month accelerator in one of the world’s largest medical centres, after completing the Melbourne Accelerator Program and raising $1 million in 2016.

The Texas Medical Centre in the US spans over 4.6 million square metres, with over 9000 beds across several facilities and 10 million patient encounters a year. Nearly $4 billion ($US3 billion) in construction is underway to further develop the precinct.
read more

Texas Medical Center Accelerator’s giant digital health cohort includes Australian contingent

In addition to domestic digital health entrepreneurs seeking to make their mark, healthcare accelerators have a lot of appeal for non-U.S. companies seeking to penetrate one of the largest healthcare markets. This cohort includes a handful of health IT and medical device startups from Australia as part of a Biobridge initiative between TMCx and the Health Informatics Society of Australia that functions as an exchange program.
read more

Asia has a unique opportunity to lead the global fight on depression

Singapore: The term mental illness strikes fear, embarrassment, and confusion. Yet mental illness is an untold opportunity in the 21st century. An opportunity to not only ease often silent suffering, but an opportunity to improve population productivity, and scale innovative health technologies.
read more

Schedule a demo